ImmunoGen Inc (IMGN) Q3 2019 Results Earnings Conference Call November 1, 2019 8:00 AM ET
Company Participants
Courtney O'Konek - Senior Director of Corporate Communications and Investor Relations
Mark Enyedy - President and Chief Executive Officer
Anna Berkenblit - Senior Vice President and Chief Medical Officer
Conference Call Participants
Boris Peaker - Cowen
Kennen MacKay - RBC Capital Markets
Andy Hsieh - William Blair
Biren Amin - Jefferies
Daniel Wolle - JP Morgan
David Ruch - SVB Leerink
Michael Schmidt - Guggenheim Securities
Joe Catanzaro - Piper Jaffray
Operator
Good morning, and welcome to ImmunoGen’s Third Quarter 2019 Financial and Operating Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Courtney O'Konek
Good morning and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and third quarter 2019 financial results. This press release and a recording of this call can be found under the Investors & Media section of our website at immunogen.com.
On the call today are Mark Enyedy, our President and CEO; and Anna Berkenblit, our Chief Medical Officer. Theresa Wingrove, our Senior Vice President of Regulatory Affairs and Quality; and Dave Foster, our Chief Accounting Officer, will also join us for Q&A.
During today's call, we will review recent progress, our third quarter financial results and highlight upcoming milestones. During the discussion, we will use forward-looking statements and our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings.
And with that, I will turn the call over to Mark.
Mark Enyedy
Thanks, Courtney. Good morning, everyone, and thank
- Read more current IMGN analysis and news
- View all earnings call transcripts